AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9274466 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 8391041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MU interferon 3 times a week for 6 months
Number of subjects: 30
Study 8391041 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study 8391041 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 MU interferon 3 times a week for 6 months
Number of subjects: 30
Study 8391041 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-therapy liver biopsy
Number of subjects: 30
Study 3551432 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 20
Study 3551432 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 20
Study 31317285 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time EEG feedback on occipital alpha lateralization
Number of subjects: 14
Study 31317285 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback
Number of subjects: 14
Study 29986040 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acid supplementation
Number of subjects: 0
Study 29986040 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 27503849 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in heart rate from supine to upright position (∆HR)
Number of subjects: 321
Study 27503849 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in heart rate from baseline to month 6
Number of subjects: 321
Study 24262498 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (1, 3, or 4 ml depending on hydrocele size) after aspiration
Number of subjects: 77
Study 24262498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 22313070 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline 1:400,000 (group A)
Number of subjects: 100
Study 22313070 — intervention group
Group type: EXPERIMENTAL
Intervention: adrenaline 1:200,000 (group B)
Number of subjects: 100
Study 22313070 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine + adrenaline 1:400,000 (group C)
Number of subjects: 100
Study 22313070 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine + adrenaline 1:200,000 (group D)
Number of subjects: 100
Study 22313070 — intervention group
Group type: COMPARATOR
Intervention: lignocaine added to infiltrating solution
Number of subjects: 100
Study 20089522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/day, orally)
Number of subjects: 252
Study 20089522 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (3.75 mg, depot i.m. injection, every 4 weeks)
Number of subjects: 252
Study 18453852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir tablets (600/150 mg or 800/200 mg twice daily) with 600 mg rifampicin once daily
Number of subjects: 40
Study 15753741 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ng/kg intravenous Escherichia coli endotoxin
Number of subjects: 8
Study 15753741 — intervention group
Group type: COMPARATOR
Intervention: Baseline day with no intervention
Number of subjects: 8
Study 14740279 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 33
Study 14740279 — intervention group
Group type: COMPARATOR
Intervention: Humulin 30/70
Number of subjects: 33
Study 10423312 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 200 microg (S)
Number of subjects: 214
Study 10423312 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 200 microg (F)
Number of subjects: 214
Study 10423312 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol 200 microg + beclomethasone 100 microg (S + B)
Number of subjects: 214
Study 10423312 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol 200 microg + ipratropium bromide 80 microg (F + IB)
Number of subjects: 214
Study 10423312 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol 50 microg (SM)
Number of subjects: 214
Study 10423312 — intervention group
Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 214
Study 7673657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 325
Study 7673657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 325
Study 7673657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg
Number of subjects: 325
Study 7673657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 2301851 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory capacity (IC) with breathholding aided by a one‐way valve
Number of subjects: 26
Study 2301851 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoached breath‐stacking (valved) maneuvers
Number of subjects: 26
Study 2301851 — intervention group
Group type: COMPARATOR
Intervention: Standard inspiratory capacity without valve or inspiratory hold
Number of subjects: 26
Study 2301851 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial coached IC effort with subsequent valved stacking of tidal efforts
Number of subjects: 26
Study 7437237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 75 mg twice daily
Number of subjects: 0
Study 7437237 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0
Study 31200665 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal only trajectory (91.4%)
Number of subjects: 384
Study 31200665 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal and postnatal trajectory (8.6%)
Number of subjects: 384
Study 31200665 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for antenatal and postnatal trajectory
Number of subjects: 384
Study 29843507 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (Group I)
Number of subjects: 80
Study 26651347 — intervention group
Group type: EXPERIMENTAL
Intervention: CLI (command line interface) with keyboard shortcuts
Number of subjects: 2
Study 26651347 — intervention group
Group type: COMPARATOR
Intervention: GUI (graphical user interface) using dropdown menu
Number of subjects: 2
Study 25354950 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Number of subjects: 180
Study 25354950 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Number of subjects: 180
Study 25354950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 22504154 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight‐bearing (WB) exercises
Number of subjects: 180
Study 22504154 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated resistance (SR) exercises
Number of subjects: 180
Study 22504154 — intervention group
Group type: COMPARATOR
Intervention: Social visits (C)
Number of subjects: 180
Study 20067667 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho All‐Flex diaphragm
Number of subjects: 45
Study 20067667 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Number of subjects: 45
Study 20067667 — intervention group
Group type: EXPERIMENTAL
Intervention: FemCap cervical cap
Number of subjects: 45
Study 20067667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical barriers (CB) overall
Number of subjects: 45
Study 19089746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 25% 1 RM
Number of subjects: 10
Study 19089746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 30% 1 RM
Number of subjects: 10
Study 19089746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 35% 1 RM
Number of subjects: 10
Study 19089746 — intervention group
Group type: EXPERIMENTAL
Intervention: Biceps curl exercise at 40% 1 RM
Number of subjects: 10
Study 19089746 — intervention group
Group type: COMPARATOR
Intervention: Isometric submaximal contraction at 50% MVC (reference contraction)
Number of subjects: 10
Study 16237763 — intervention group
Group type: EXPERIMENTAL
Intervention: Helico Blot 2.1
Number of subjects: 33
Study 16237763 — intervention group
Group type: EXPERIMENTAL
Intervention: CagA antigen and Helico Blot 2.1
Number of subjects: 33
Study 12165596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 30% glucose (0.3 mL)
Number of subjects: 40
Study 12165596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.3 mL of sterile water)
Number of subjects: 40
Study 12165596 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 30% glucose (0.3 mL) plus pacifier
Number of subjects: 40
Study 10208545 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalographic (MEG) signals measured from the left frontal area
Number of subjects: 0
Study 10208545 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of MEG response
Number of subjects: 0
Study 7870752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory posteroanterior mobilizations under different conditions of stiffness
Number of subjects: 10
Study 2221645 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 50
Study 2221645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 375679 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 60
Study 375679 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 60
Study 6760120 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine extracted monocomponent insulins
Number of subjects: 0
Study 6760120 — intervention group
Group type: EXPERIMENTAL
Intervention: Human semi‐synthetic insulins
Number of subjects: 0
Study 6760120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of insulin therapy
Number of subjects: 0
Study 31701593 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally interrupted direct oral anticoagulation (DOAC) therapy
Number of subjects: 584
Study 31701593 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted direct oral anticoagulation (DOAC) therapy
Number of subjects: 584
Study 29177507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobe-specific nodal dissection
Number of subjects: 1700
Study 29177507 — intervention group
Group type: COMPARATOR
Intervention: Systematic nodal dissection
Number of subjects: 1700
Study 27317706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg s.c. injection)
Number of subjects: 50
Study 27317706 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 50
Study 24338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6 above the 75th percentile
Number of subjects: 400
Study 24338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum CRP above the 75th percentile
Number of subjects: 400
Study 24338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6, CRP, or MPO above the 75th percentile
Number of subjects: 400
Study 24338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum IL‐6, CRP, or MPO
Number of subjects: 400
Study 22709272 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% nicotinamide lotion
Number of subjects: 50
Study 22709272 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral nicotinamide
Number of subjects: 50
Study 22709272 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 50
Study 22709272 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 20610752 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic responses linked with perceptual priming
Number of subjects: 0
Study 20610752 — intervention group
Group type: EXPERIMENTAL
Intervention: Different potentials recorded during initial presentations
Number of subjects: 0
Study 18274646 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids plus glucose (AAG) dialysate
Number of subjects: 6
Study 18274646 — intervention group
Group type: COMPARATOR
Intervention: Glucose alone (control)
Number of subjects: 6
Study 15732070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine with guided self-help
Number of subjects: 50
Study 15732070 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine without guided self-help
Number of subjects: 50
Study 14609009 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 48
Study 14609009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10544229 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 0
Study 10544229 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7594660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 24-7429 (Tat antagonist) at 75, 150, or 300 mg/day
Number of subjects: 96
Study 7594660 — intervention group
Group type: COMPARATOR
Intervention: Nucleoside analogue (zidovudine or didanosine)
Number of subjects: 96
Study 2087280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 40
Study 2087280 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 40
Study 314399 — intervention group
Group type: EXPERIMENTAL
Intervention: Enelbin‐Rheuma‐ointment
Number of subjects: 100
Study 314399 — intervention group
Group type: COMPARATOR
Intervention: Reference ointment
Number of subjects: 100
Study 30169322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-exposure everolimus (3-7 ng/mL)
Number of subjects: 299
Study 30169322 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exposure everolimus (9-15 ng/mL)
Number of subjects: 299
Study 30169322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 30169322 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3-15 ng/mL) during extension phase
Number of subjects: 299
Study 27694157 — intervention group
Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles)
Number of subjects: 37
Study 27694157 — intervention group
Group type: EXPERIMENTAL
Intervention: Linsitinib (150 mg orally twice daily until progression)
Number of subjects: 37
Study 26627881 — intervention group
Group type: EXPERIMENTAL
Intervention: POC-Troponin
Number of subjects: 601
Study 26627881 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 601
Study 23553863 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan (VAL)
Number of subjects: 26
Study 23553863 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study 20603462 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with coaching
Number of subjects: 362
Study 20603462 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study 19086108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with oestradiol and noretisterone acetate, vitamin D3 and calcium
Number of subjects: 88
Study 19086108 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 and calcium alone
Number of subjects: 88
Study 19086108 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 88
Study 16647414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention (BI)
Number of subjects: 49
Study 16647414 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard of Care (ESC)
Number of subjects: 49
Study 12600843 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g high-performance inulin/d
Number of subjects: 8
Study 12600843 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8
Study 11005114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination at the 18th and 32nd week of pregnancy in addition to routine antenatal care
Number of subjects: 1628
Study 11005114 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care with referral for ultrasound on clinical indication
Number of subjects: 1628
Study 11005114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 1628
Study 11005114 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 1628
Study 9526603 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 0
Study 9526603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8407216 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 25/6.25 mg
Number of subjects: 20
Study 8407216 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa 50/12.5 mg
Number of subjects: 20
Study 8407216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Tums)
Number of subjects: 20
Study 3940504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (300 mg orally) with zinc sulfate
Number of subjects: 12
Study 3940504 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (30 mL orally) with zinc sulfate
Number of subjects: 12
Study 3940504 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulfate alone
Number of subjects: 12
Study 29630132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane combined with remifentanil
Number of subjects: 150
Study 29630132 — intervention group
Group type: COMPARATOR
Intervention: Propofol combined with remifentanil
Number of subjects: 150
Study 27602929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prepared, 1-day, low-residue diets with a same-day 2.0-L single-dose of polyethylene glycol (Group A)
Number of subjects: 180
Study 27602929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diets plus 2.0 L of polyethylene glycol (Group B)
Number of subjects: 180
Study 27602929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepackaged low-residue diets plus 1.5 L of polyethylene glycol (Group C)
Number of subjects: 180
Study 24258020 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture/Biomembrane
Number of subjects: 64
Study 24258020 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 64
Study 23506436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion (10 g · kgBM(‐1) of ice slurry < 1°C)
Number of subjects: 9
Study 23506436 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluid (32‐34°C)
Number of subjects: 9
Study 23506436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry ingestion
Number of subjects: 9
Study 23506436 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluid
Number of subjects: 9
Study 20019315 — intervention group
Group type: COMPARATOR
Intervention: Online untailored program (arm 1)
Number of subjects: 2540
Study 20019315 — intervention group
Group type: COMPARATOR
Intervention: Tailored behavioral intervention (arm 2)
Number of subjects: 2540
Study 20019315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention plus motivational interviewing‐based counseling via e‐mail (arm 3)
Number of subjects: 2540
Study 18155205 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 65
Study 18155205 — intervention group
Group type: COMPARATOR
Intervention: ERCP
Number of subjects: 65
Study 16708558 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroseptal myocardial infarction (aMI) group
Number of subjects: 68
Study 16708558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction (iMI) group
Number of subjects: 68
Study 12693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program consisting of 6 sessions of 30 minutes each over 4 weeks to teach discrimination, identification, expression, and application of facial expression cues.
Number of subjects: 30
Study 12693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 30
Study 11040014 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective stent implantation
Number of subjects: 300
Study 11040014 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 300
Study 11040014 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from balloon angioplasty to stenting
Number of subjects: 300
Study 11040014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (stent and balloon angioplasty)
Number of subjects: 300
Study 9275430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TIL) and chemotherapy
Number of subjects: 25
Study 9275430 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 25
Study 1739568 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 32
Study 1739568 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 32
Study 6730874 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine
Number of subjects: 0
Study 6730874 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study 31615471 — intervention group
Group type: COMPARATOR
Intervention: fTcSC
Number of subjects: 116
Study 29995356 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera extract (WSE) 1,000 mg/d
Number of subjects: 66
Study 29995356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27580669 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Occupational Therapy (PT and OT) NHS services, n=381
Number of subjects: 762
Study 27580669 — intervention group
Group type: COMPARATOR
Intervention: No therapy, n=381
Number of subjects: 762
Study 24526592 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-weight mesh (LWM)
Number of subjects: 0
Study 24526592 — intervention group
Group type: COMPARATOR
Intervention: Heavy-weight mesh (HWM)
Number of subjects: 0
Study 21324655 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS to the VMPFC
Number of subjects: 13
Study 21324655 — intervention group
Group type: COMPARATOR
Intervention: sham‐rTMS
Number of subjects: 13
Study 21324655 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS to the vertex
Number of subjects: 13
Study 20142595 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subcutaneous pegfilgrastim injection (100 microg/kg)
Number of subjects: 44
Study 20142595 — intervention group
Group type: COMPARATOR
Intervention: Daily subcutaneous filgrastim administration (5 microg/kg)
Number of subjects: 44
Study 16936584 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted weightbearing combined with intensive physiotherapy from the first day after surgery
Number of subjects: 29